|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Suva LJ, Washam C, Nicholas RW and Griffin
RJ: Bone metastasis: mechanisms and therapeutic opportunities. Nat
Rev Endocrinol. 7:208–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bickels J, Dadia S and Lidar Z: Surgical
management of metastatic bone disease. J Bone Joint Surg Am.
91:1503–1516. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Santini D, Galluzzo S, Zoccoli A, et al:
New molecular targets in bone metastases. Cancer Treat Rev.
36(Suppl 3): S6–S10. 2010. View Article : Google Scholar
|
|
5
|
Jin JK, Dayyani F and Gallick GE: Steps in
prostate cancer progression that lead to bone metastasis. Int J
Cancer. 128:2545–2561. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jenei V, Sherwood V, Howlin J, et al: A
t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as
a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc
Natl Acad Sci USA. 106:19473–19478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bitler BG, Nicodemus JP, Li H, et al:
Wnt5a suppresses epithelial ovarian cancer by promoting cellular
senescence. Cancer Res. 71:6184–6194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weeraratna AT, Jiang Y, Hostetter G, et
al: Wnt5a signaling directly affects cell motility and invasion of
metastatic melanoma. Cancer Cell. 1:279–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Q, Symes AJ, Kane CA, et al: A novel
role for Wnt/Ca2+ signaling in actin cytoskeleton
remodeling and cell motility in prostate cancer. PLoS One.
5:e104562010.PubMed/NCBI
|
|
11
|
Li D, Dai K and Tang T: Effects of dextran
on proliferation and osteogenic differentiation of human bone
marrow-derived mesenchymal stromal cells. Cytotherapy. 10:587–596.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
13
|
Kikuchi A, Yamamoto H, Sato A and
Matsumoto S: Wnt5a: its signalling, functions and implication in
diseases. Acta Physiol (Oxf). 204:17–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Witze ES, Litman ES, Argast GM, Moon RT
and Ahn NG: Wnt5a control of cell polarity and directional movement
by polarized redistribution of adhesion receptors. Science.
320:365–369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roarty K and Serra R: Wnt5a is required
for proper mammary gland development and TGF-beta-mediated
inhibition of ductal growth. Development. 134:3929–3939. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McDonald S and Silver A: The opposing
roles of Wnt-5a in cancer. Br J Cancer. 101:209–214. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Da Forno PD, Pringle JH, Hutchinson P, et
al: WNT5A expression increases during melanoma progression and
correlates with outcome. Clin Cancer Res. 14:5825–5832.
2008.PubMed/NCBI
|
|
18
|
O’Connell MP, Fiori JL, Xu M, et al: The
orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in
metastatic melanoma. Oncogene. 29:34–44. 2010.PubMed/NCBI
|
|
19
|
Kurayoshi M, Oue N, Yamamoto H, et al:
Expression of Wnt-5a is correlated with aggressiveness of gastric
cancer by stimulating cell migration and invasion. Cancer Res.
66:10439–10448. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ripka S, König A, Buchholz M, et al:
WNT5A-target of CUTL1 and potent modulator of tumor cell migration
and invasion in pancreatic cancer. Carcinogenesis. 28:1178–1187.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hanaki H, Yamamoto H, Sakane H, et al: An
anti-Wnt5a antibody suppresses metastasis of gastric cancer cells
in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer
Ther. 11:298–307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng C, Zhang X, Yu H, Wu D and Zheng J:
Wnt5a as a predictor in poor clinical outcome of patients and a
mediator in chemoresistance of ovarian cancer. Int J Gynecol
Cancer. 21:280–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kamino M, Kishida M, Kibe T, et al: Wnt-5a
signaling is correlated with infiltrative activity in human glioma
by inducing cellular migration and MMP-2. Cancer Sci. 102:540–548.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ying J, Li H, Yu J, et al: WNT5A exhibits
tumor-suppressive activity through antagonizing the
Wnt/beta-catenin signaling, and is frequently methylated in
colorectal cancer. Clin Cancer Res. 14:55–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blanc E, Roux GL, Bénard J and Raguénez G:
Low expression of Wnt-5a gene is associated with high-risk
neuroblastoma. Oncogene. 24:1277–1283. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jönsson M, Dejmek J, Bendahl PO and
Andersson T: Loss of Wnt-5a protein is associated with early
relapse in invasive ductal breast carcinomas. Cancer Res.
62:409–416. 2002.PubMed/NCBI
|
|
27
|
Deng G, Li ZQ, Zhao C, et al: WNT5A
expression is regulated by the status of its promoter methylation
in leukaemia and can inhibit leukemic cell malignant proliferation.
Oncol Rep. 25:367–376. 2011.PubMed/NCBI
|
|
28
|
Syed Khaja AS, Helczynski L, Edsjö A, et
al: Elevated level of Wnt5a protein in localized prostate cancer
tissue is associated with better outcome. PLoS One.
6:e265392011.PubMed/NCBI
|
|
29
|
Yamamoto H, Oue N, Sato A, et al: Wnt5a
signaling is involved in the aggressiveness of prostate cancer and
expression of metalloproteinase. Oncogene. 29:2036–2046. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang S, Wang J, Bilen MA, Lin SH, Stupp
SI and Satcher RL: Modulation of prostate cancer cell gene
expression by cell-to-cell contact with bone marrow stromal cells
or osteoblasts. Clin Exp Metastasis. 26:993–1004. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhau HE, He H, Wang CY, et al: Human
prostate cancer harbors the stem cell properties of bone marrow
mesenchymal stem cells. Clin Cancer Res. 17:2159–2169. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hart CA, Brown M, Bagley S, Sharrard M and
Clarke NW: Invasive characteristics of human prostatic epithelial
cells: understanding the metastatic process. Br J Cancer.
92:503–512. 2005.PubMed/NCBI
|
|
33
|
van den Hoogen C, van der Horst G, Cheung
H, Buijs JT, Pelger RC and van der Pluijm G: Integrin αv expression
is required for the acquisition of a metastatic stem/progenitor
cell phenotype in human prostate cancer. Am J Pathol.
179:2559–2568. 2011.
|
|
34
|
Mochizuki H, Matsubara A, Teishima J, et
al: Interaction of ligand-receptor system between
stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human
prostate cancer: a possible predictor of metastasis. Biochem
Biophys Res Commun. 320:656–663. 2004. View Article : Google Scholar
|
|
35
|
Taichman RS, Cooper C, Keller ET, Pienta
KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived
factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Cancer Res. 62:1832–1837. 2002.PubMed/NCBI
|
